Cochlear
CompanyAustralia
Cochlear develops 2 assets, the furthest in human trials (CI622D in bilateral hearing loss). Mostly device acting on NR3C1 and inflammation; based in Australia.
- Assets
- 2
- Furthest
- Human trials
- Trials
- 2
- Signals
- 0
Pipeline
2Dexamethasone-eluting cochlear implant electrode to reduce local inflammation and electrical impedance
Human trialsDeviceNR3C1Inflammationbilateral hearing lossbilateral sensorineural hearing loss
Totally implantable cochlear implant system for restoring auditory perception without external components
Human trialsDevicebilateral sensorineural hearing loss
Full company profiles: pipeline, trials, funding and people.
See Pro- Evidence behind the mechanisms2
- Trials2
- Signals1
- Integrity notices1
- Similar companies6
Updated 7 Oct 2026 · 4 sources